Peptide Schedule
Bradykinin9 residuesRPPGFSPFREach bubble = one amino acid. Size = residue mass. Color = chemical class.Bradykinin
Benefits
About Bradykinin
Bradykinin is a 9-amino-acid vasoactive peptide (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) generated through the enzymatic cleavage of high-molecular-weight kininogen (HMWK) by the serine protease kallikrein. First isolated and characterized by Maurício Rocha e Silva and colleagues in 1949, its name derives from the Greek "bradys" (slow) and "kinein" (to move), referring to its slow contraction of smooth muscle. Bradykinin is a central mediator of the kallikrein-kinin system (KKS), one of the most important vasoactive pathways in human physiology. It acts primarily through two G-protein coupled receptors: the constitutively expressed B2 receptor and the inducible B1 receptor, which is upregulated during tissue injury and inflammation. Through the B2 receptor, bradykinin triggers potent vasodilation by stimulating endothelial nitric oxide synthase (eNOS) and prostacyclin (PGI2) release, producing profound effects on vascular tone and blood pressure. Bradykinin is rapidly degraded in vivo by angiotensin-converting enzyme (ACE, also known as kininase II), which cleaves it into inactive fragments. This relationship between ACE and bradykinin is clinically significant — ACE inhibitors, among the most widely prescribed cardiovascular drugs, exert part of their therapeutic benefit by preventing bradykinin degradation, thereby augmenting its vasodilatory effects. The peptide also plays a critical role in hereditary angioedema (HAE), where deficiency of C1-inhibitor leads to excessive bradykinin generation and severe episodic swelling. This has led to the development of the B2 receptor antagonist icatibant (Firazyr) as an FDA-approved treatment for HAE. Bradykinin has been implicated in the dry cough side effect of ACE inhibitors, allergic responses, pain sensitization, and more recently in the proposed "bradykinin storm" hypothesis related to severe inflammatory respiratory conditions.
Who Should Consider Bradykinin
- Cardiovascular researchers studying endothelial function and vasodilation
- Scientists investigating the kallikrein-kinin system and ACE inhibitor mechanisms
- Clinicians researching hereditary angioedema pathophysiology
- Pain researchers studying nociceptor sensitization and inflammatory hyperalgesia
- Pharmacologists developing kinin receptor modulators
- Researchers exploring vascular permeability and inflammatory edema
How Bradykinin Works
Bradykinin exerts its biological effects primarily through activation of two G-protein coupled receptors: the B2 receptor (constitutive) and B1 receptor (inducible). Upon binding the B2 receptor on vascular endothelial cells, bradykinin activates Gαq signaling, which stimulates phospholipase C (PLC) to generate inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3-mediated intracellular calcium release activates endothelial nitric oxide synthase (eNOS), producing nitric oxide (NO) that diffuses to underlying smooth muscle and activates guanylyl cyclase, leading to cGMP-dependent vasodilation. Simultaneously, phospholipase A2 activation releases arachidonic acid, which is converted to prostacyclin (PGI2) by cyclooxygenase — a second vasodilatory pathway. Bradykinin also stimulates tissue plasminogen activator (tPA) release from endothelial cells, promoting fibrinolysis. In sensory neurons, B2 receptor activation sensitizes TRPV1 channels and enhances sodium channel activity, lowering the pain threshold and producing hyperalgesia. The B1 receptor, upregulated by cytokines (IL-1β, TNF-α) during inflammation, binds des-Arg9-bradykinin (a metabolite) and sustains chronic inflammatory signaling through NF-κB activation. Bradykinin is rapidly inactivated by ACE (kininase II), which cleaves the Pro7-Phe8 bond, and by carboxypeptidase N (kininase I), which removes the C-terminal arginine.
What to Expect
Immediate B2 receptor activation upon administration. Rapid onset of vasodilation, nitric oxide release, and drop in local or systemic blood pressure. Peak plasma levels achieved almost instantaneously with IV/IA delivery. Degradation by ACE begins immediately.
Maximal vasodilatory response observed. Increased vascular permeability and plasma extravasation at target tissue. Nociceptor sensitization and pain signaling detectable. Most of the administered peptide has been degraded by this point.
Hemodynamic parameters begin returning to baseline following cessation of infusion. Residual inflammatory signaling may persist via prostaglandin and NO pathways. Localized edema may take longer to resolve.
Direct peptide effects have fully dissipated. Secondary inflammatory mediators (prostaglandins, cytokines) may sustain mild local inflammation. B1 receptor upregulation begins if tissue injury or cytokine exposure is ongoing.
With repeated daily dosing in research protocols, measurable upregulation of B1 receptors at target tissue. Shift from acute B2-mediated to chronic B1-mediated signaling may alter inflammatory profile. Full vascular recovery expected within 24 hours of last dose.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 25mcg | Daily |
| Moderate | 50mcg | Daily |
| Aggressive | 100mcg | Daily |
Note: Bradykinin is an endogenous 9-amino-acid peptide (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) of the kallikrein-kinin system. It is one of the most potent endogenous vasodilators known and plays central roles in inflammation, pain signaling, vascular permeability, and blood pressure regulation. Due to its extraordinarily short half-life of approximately 15-30 seconds — rapidly degraded by kininase II (ACE) and kininase I — exogenous administration for therapeutic purposes is extremely challenging. Most clinical strategies targeting this pathway involve either ACE inhibitors (which raise endogenous bradykinin levels) or B2 receptor antagonists like icatibant (for hereditary angioedema). Direct bradykinin administration remains strictly a research tool for studying vascular physiology, pain mechanisms, and inflammation. Handle with appropriate caution given its potent hypotensive and pro-inflammatory effects.
How to Inject Bradykinin
Bradykinin is used exclusively in controlled research environments. Reconstitute lyophilized bradykinin acetate with bacteriostatic water to desired concentration. In clinical research protocols, bradykinin is most commonly administered via intra-arterial infusion into the brachial or coronary arteries to assess endothelial function and vasodilatory capacity. Intravenous administration produces systemic effects and requires continuous blood pressure monitoring. Subcutaneous injection is occasionally used in pain research models. Due to the ultra-short half-life (~15-30 seconds), continuous infusion is generally required to maintain steady-state plasma levels. Start at the lowest dose and titrate slowly. Emergency vasopressor support and airway management equipment must be immediately available given the risk of severe hypotension and angioedema. Never administer outside a clinical or research facility.
Cycling Protocol
Due to extreme vasoactive potency and risk of B1 receptor upregulation with repeated exposure, only very short research cycles are appropriate. Extended use is not recommended. Continuous hemodynamic monitoring required during administration.
Pharmacokinetics
Source: Murphey et al., J Pharmacol Exp Ther, 2000 — measured plasma bradykinin half-life ~15-27 seconds in humans
Loading the interactive decay curve.
Side Effects
Bradykinin is an extremely potent vasoactive peptide and exogenous administration carries significant risk. Profound hypotension is the primary concern, as bradykinin causes rapid vasodilation and can lead to dangerous drops in blood pressure, especially with intravenous delivery. Increased vascular permeability may cause localized or systemic edema, including angioedema of the face, tongue, and airways — potentially life-threatening. Pain and burning at the injection site are common due to direct nociceptor sensitization through B2 and B1 receptors. Bronchoconstriction may occur, particularly in individuals with asthma or reactive airway disease. Flushing, tachycardia (reflexive), nausea, and headache are frequently reported in research settings. Mast cell activation and histamine release can compound allergic-type reactions. Due to its ultra-short half-life, effects are generally transient but can be severe during the acute window. Repeated exposure may upregulate B1 receptors, potentially amplifying inflammatory responses over time.
Contraindications
- Hypotension or hemodynamic instability — bradykinin causes profound vasodilation
- History of angioedema (hereditary or ACE inhibitor-induced)
- Concurrent ACE inhibitor therapy — dramatically potentiates bradykinin effects
- Asthma or reactive airway disease — risk of bronchoconstriction
- Pregnancy — vasoactive effects may compromise placental perfusion
- Severe cardiovascular disease or recent myocardial infarction
Drug Interactions
- ACE inhibitors (enalapril, lisinopril, ramipril) — prevent bradykinin degradation, markedly potentiating effects and risk of angioedema
- ARBs (losartan, valsartan) — may modestly potentiate bradykinin via AT2 receptor crosstalk
- NSAIDs (ibuprofen, aspirin) — block prostacyclin synthesis, partially attenuating bradykinin-mediated vasodilation
- Icatibant (B2 receptor antagonist) — directly blocks bradykinin effects, used as rescue in research protocols
- Neprilysin inhibitors (sacubitril) — reduce bradykinin degradation, increasing accumulation
- Vasopressors (norepinephrine, phenylephrine) — may be required to counteract severe hypotension
Storage & Stability
Molecular Profile
Related Peptides
References
- Bradykinin and its role in cardiovascular diseaseReview
- The kallikrein-kinin system: current and future pharmacological targetsReview
- Bradykinin B1 and B2 receptors: role in pain, inflammation and tissue remodelingReview
- ACE inhibition, ACE2 and bradykinin: a review from a clinical perspectiveReview
- Icatibant for the treatment of hereditary angioedemaReview